Genetic analysis of vitreoretinal lymphoma
| Project/Area Number |
16K11281
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TANAKA RIE 東京大学, 医学部附属病院, 助教 (70746388)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
蕪城 俊克 東京大学, 医学部附属病院, 准教授 (00280941)
田岡 和城 東京大学, 医学部附属病院, 助教 (30529178)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 眼内悪性リンパ腫 / 遺伝子解析 / 診断 / デジタルPCR / 遺伝子変異 / エクソーム解析 / 網羅的遺伝子解析 / 原因遺伝子 / 次世代シークエンサー / 硝子体液 |
|---|
| Outline of Final Research Achievements |
Eighty-six patients diagnosed as VRL were analyzed for mutation profiles and clinical outcome due to treatments.
Mutations of 4 genes were frequently found in VRL: MYD88 (61%), CD79B (43%), PIM1 (25%), and BTG2 (19%). CD79B mutated patients had 4 year recurrence-free survival rates of 35%, as compared to 79% of non-mutated subjects (p=0.029). Importantly, cases with all of MYD88, CD79B, and BTG2 mutations unexceptionally resulted in relapse, even after intensive multimodality treatments.
|
| Academic Significance and Societal Importance of the Research Achievements |
硝子体手術で採取された検体を用いて眼内悪性リンパ腫の診断は行うが、病理細胞診のみでの診断は難しいことが知られている。硝子体手術で採取された細胞に対して、遺伝子変異を検索することが、眼内悪性リンパ腫の補助診断になる可能性が示唆された。また、遺伝子変異のタイプにより、リンパ腫の再発率に差を認めることから、予後予測にも役立つと考えられる。
|
Report
(4 results)
Research Products
(70 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Serum cytokine concentrations before and after starting of infliximab therapy.2016
Author(s)
Hisae Nakahara, Toshikatsu Kaburaki, Rie Tanaka, Kazuyoshi Ootomo, Mitsuko Takamoto, Ayako Karakawa, Kimiko Okinaga, Junko Matsuda, Yujiro Fujino, Hidetoshi Kawashima, Makoto Aihara.
Organizer
ARVO2016
Place of Presentation
Seattle, USA
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
[Presentation] Long term Safety and Efficacy of Adalimumab in Non-infectious Uveitis patients.2016
Author(s)
蕪城俊克 , 後藤 浩, Eric B. Suhler, Glenn J. Jaffe, Quan Dong Nguyen, Antoine P. Brezin, Manfred Zierhut, Albert Vitale, Mirjam E. van Velthoven, Alfredo Adan, Lyndell Lim, Michal Kramer, Ariel Schlaen, Eric Fortin, Cristina Muccioli, Anne Camez, Alexandra Song, Martina Kron, Samir Tari, Andrew D. Dick.
Organizer
第70回日本臨床眼科学会総会
Place of Presentation
京都
Related Report
-
-
-
-
